Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017
BACKGROUND: Tuberculosis preventive treatment (TPT) reduces the development of tuberculosis (TB) disease and mortality in people living with human immunodeficiency virus (HIV) infection. Despite this known effectiveness, global uptake of TPT has been slow. We aimed to assess current status of TPT im...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2019-12, Vol.23 (12), p.1308-1313 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1313 |
|---|---|
| container_issue | 12 |
| container_start_page | 1308 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 23 |
| creator | Surie, D. Interrante, J. D. Pathmanathan, I. Patel, M. R. Anyalechi, G. Cavanaugh, J. S. Kirking, H. L. |
| description | BACKGROUND: Tuberculosis preventive treatment (TPT) reduces the development of tuberculosis (TB) disease and mortality in people living with human immunodeficiency virus (HIV) infection. Despite this known effectiveness, global uptake of TPT has been slow. We aimed to assess
current status of TPT implementation in countries supported by the US President's Emergency Plan for AIDS Relief (PEPFAR).METHODS: We surveyed TB-HIV program staff at US Centers for Disease Control and Prevention (CDC) country offices in 42 PEPFAR-supported countries about current
TPT policies, practices, and barriers to implementation. Surveys completed from July to December 2017 were analyzed.RESULTS: Of 42 eligible PEPFAR-supported countries, staff from 35 (83%) CDC country offices completed the survey. TPT was included in national guidelines in 33 (94%)
countries, but only 21 (60%) reported nationwide programmatic TPT implementation. HIV programs led TPT implementation in 20/32 (63%) countries, but TB programs led drug procurement in 18/32 (56%) countries. Stock outs were frequent, as 21/28 (75%) countries reported at least one isoniazid
stock out in the previous year.CONCLUSION: Despite widespread inclusion of TPT in guidelines, programmatic TPT implementation lags. Successful scale-up of TPT requires uninterrupted drug supply chains facilitated by improved leadership and coordination between HIV and TB programs. |
| doi_str_mv | 10.5588/ijtld.19.0018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_ingen</sourceid><recordid>TN_cdi_proquest_miscellaneous_2338091784</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2019/00000023/00000012/art00013</ingid><sourcerecordid>2325598052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-4c3e2f5a0cf3164333228bd2af98c3debbf3b130c6c5d9ad4e10ec03034258ce3</originalsourceid><addsrcrecordid>eNp1kcuLFDEQh4Mo7rp69CoNXjzYYyrV2U6Osj5hQRE9h3S6esnQjzGPAf3rTU-PCoIhkCJ8-VL8irGnwHdSKvXK79PY70DvOAd1j12CAlm3WvD7peairbEFfcEexbjnXABA-5BdIOiyQV4y-ryM3nmKL6tDsC55R7Gyc191NgRPIVZpqfx0GGmiOfn5rkq5o-DyuEQfyxs6rvdHqlIgm1aoRlm5Jc8pnLSCQ_uYPRjsGOnJ-bxi3969_Xrzob799P7jzevb2jWyTXXjkMQgLXcDwnWDiEKorhd20MphT103YAfI3bWTvbZ9Q8DJceTYCKkc4RV7sXkPYfmeKSYz-ehoHO1MS45GICquoVVNQZ__g-6XHObSXaGElFpxKQpVb5QLS4yBBnMIfrLhhwFu1vzNKX8D2qz5F_7Z2Zq7ifo_9O_AC_BlA0qUJSv791fvjM_2JCtjW6dmjgJnEEaUuXElpAHJlelpsHlMJtlg7n6aCFikb_4n3Yxbk2USa5vrEnguit6GtBaIvwD_j7MN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2325598052</pqid></control><display><type>article</type><title>Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Surie, D. ; Interrante, J. D. ; Pathmanathan, I. ; Patel, M. R. ; Anyalechi, G. ; Cavanaugh, J. S. ; Kirking, H. L.</creator><creatorcontrib>Surie, D. ; Interrante, J. D. ; Pathmanathan, I. ; Patel, M. R. ; Anyalechi, G. ; Cavanaugh, J. S. ; Kirking, H. L.</creatorcontrib><description>BACKGROUND: Tuberculosis preventive treatment (TPT) reduces the development of tuberculosis (TB) disease and mortality in people living with human immunodeficiency virus (HIV) infection. Despite this known effectiveness, global uptake of TPT has been slow. We aimed to assess
current status of TPT implementation in countries supported by the US President's Emergency Plan for AIDS Relief (PEPFAR).METHODS: We surveyed TB-HIV program staff at US Centers for Disease Control and Prevention (CDC) country offices in 42 PEPFAR-supported countries about current
TPT policies, practices, and barriers to implementation. Surveys completed from July to December 2017 were analyzed.RESULTS: Of 42 eligible PEPFAR-supported countries, staff from 35 (83%) CDC country offices completed the survey. TPT was included in national guidelines in 33 (94%)
countries, but only 21 (60%) reported nationwide programmatic TPT implementation. HIV programs led TPT implementation in 20/32 (63%) countries, but TB programs led drug procurement in 18/32 (56%) countries. Stock outs were frequent, as 21/28 (75%) countries reported at least one isoniazid
stock out in the previous year.CONCLUSION: Despite widespread inclusion of TPT in guidelines, programmatic TPT implementation lags. Successful scale-up of TPT requires uninterrupted drug supply chains facilitated by improved leadership and coordination between HIV and TB programs.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.19.0018</identifier><identifier>PMID: 31931915</identifier><language>eng</language><publisher>France: International Union Against Tuberculosis and Lung Disease</publisher><subject>Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome ; AIDS ; Communication Barriers ; Developing Countries ; Disease control ; Emergency preparedness ; Global Health ; Guidelines ; Health Policy ; Health Promotion ; HIV ; HIV Infections ; Human immunodeficiency virus ; Humans ; International Cooperation ; Isoniazid ; isoniazid preventive therapy ; Leadership ; Offices ; Policies ; Policy ; Polls & surveys ; Procurement ; Supply chains ; Surveys And Questionnaires ; Tuberculosis ; Tuberculosis, Pulmonary - prevention & control ; Viruses</subject><ispartof>The international journal of tuberculosis and lung disease, 2019-12, Vol.23 (12), p.1308-1313</ispartof><rights>Copyright International Union against Tuberculosis and Lung Disease (IUATLD) Dec 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-4c3e2f5a0cf3164333228bd2af98c3debbf3b130c6c5d9ad4e10ec03034258ce3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31931915$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Surie, D.</creatorcontrib><creatorcontrib>Interrante, J. D.</creatorcontrib><creatorcontrib>Pathmanathan, I.</creatorcontrib><creatorcontrib>Patel, M. R.</creatorcontrib><creatorcontrib>Anyalechi, G.</creatorcontrib><creatorcontrib>Cavanaugh, J. S.</creatorcontrib><creatorcontrib>Kirking, H. L.</creatorcontrib><title>Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>BACKGROUND: Tuberculosis preventive treatment (TPT) reduces the development of tuberculosis (TB) disease and mortality in people living with human immunodeficiency virus (HIV) infection. Despite this known effectiveness, global uptake of TPT has been slow. We aimed to assess
current status of TPT implementation in countries supported by the US President's Emergency Plan for AIDS Relief (PEPFAR).METHODS: We surveyed TB-HIV program staff at US Centers for Disease Control and Prevention (CDC) country offices in 42 PEPFAR-supported countries about current
TPT policies, practices, and barriers to implementation. Surveys completed from July to December 2017 were analyzed.RESULTS: Of 42 eligible PEPFAR-supported countries, staff from 35 (83%) CDC country offices completed the survey. TPT was included in national guidelines in 33 (94%)
countries, but only 21 (60%) reported nationwide programmatic TPT implementation. HIV programs led TPT implementation in 20/32 (63%) countries, but TB programs led drug procurement in 18/32 (56%) countries. Stock outs were frequent, as 21/28 (75%) countries reported at least one isoniazid
stock out in the previous year.CONCLUSION: Despite widespread inclusion of TPT in guidelines, programmatic TPT implementation lags. Successful scale-up of TPT requires uninterrupted drug supply chains facilitated by improved leadership and coordination between HIV and TB programs.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome</subject><subject>AIDS</subject><subject>Communication Barriers</subject><subject>Developing Countries</subject><subject>Disease control</subject><subject>Emergency preparedness</subject><subject>Global Health</subject><subject>Guidelines</subject><subject>Health Policy</subject><subject>Health Promotion</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Isoniazid</subject><subject>isoniazid preventive therapy</subject><subject>Leadership</subject><subject>Offices</subject><subject>Policies</subject><subject>Policy</subject><subject>Polls & surveys</subject><subject>Procurement</subject><subject>Supply chains</subject><subject>Surveys And Questionnaires</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - prevention & control</subject><subject>Viruses</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcuLFDEQh4Mo7rp69CoNXjzYYyrV2U6Osj5hQRE9h3S6esnQjzGPAf3rTU-PCoIhkCJ8-VL8irGnwHdSKvXK79PY70DvOAd1j12CAlm3WvD7peairbEFfcEexbjnXABA-5BdIOiyQV4y-ryM3nmKL6tDsC55R7Gyc191NgRPIVZpqfx0GGmiOfn5rkq5o-DyuEQfyxs6rvdHqlIgm1aoRlm5Jc8pnLSCQ_uYPRjsGOnJ-bxi3969_Xrzob799P7jzevb2jWyTXXjkMQgLXcDwnWDiEKorhd20MphT103YAfI3bWTvbZ9Q8DJceTYCKkc4RV7sXkPYfmeKSYz-ehoHO1MS45GICquoVVNQZ__g-6XHObSXaGElFpxKQpVb5QLS4yBBnMIfrLhhwFu1vzNKX8D2qz5F_7Z2Zq7ifo_9O_AC_BlA0qUJSv791fvjM_2JCtjW6dmjgJnEEaUuXElpAHJlelpsHlMJtlg7n6aCFikb_4n3Yxbk2USa5vrEnguit6GtBaIvwD_j7MN</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Surie, D.</creator><creator>Interrante, J. D.</creator><creator>Pathmanathan, I.</creator><creator>Patel, M. R.</creator><creator>Anyalechi, G.</creator><creator>Cavanaugh, J. S.</creator><creator>Kirking, H. L.</creator><general>International Union Against Tuberculosis and Lung Disease</general><general>International Union against Tuberculosis and Lung Disease (IUATLD)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20191201</creationdate><title>Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017</title><author>Surie, D. ; Interrante, J. D. ; Pathmanathan, I. ; Patel, M. R. ; Anyalechi, G. ; Cavanaugh, J. S. ; Kirking, H. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-4c3e2f5a0cf3164333228bd2af98c3debbf3b130c6c5d9ad4e10ec03034258ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome</topic><topic>AIDS</topic><topic>Communication Barriers</topic><topic>Developing Countries</topic><topic>Disease control</topic><topic>Emergency preparedness</topic><topic>Global Health</topic><topic>Guidelines</topic><topic>Health Policy</topic><topic>Health Promotion</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Isoniazid</topic><topic>isoniazid preventive therapy</topic><topic>Leadership</topic><topic>Offices</topic><topic>Policies</topic><topic>Policy</topic><topic>Polls & surveys</topic><topic>Procurement</topic><topic>Supply chains</topic><topic>Surveys And Questionnaires</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - prevention & control</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Surie, D.</creatorcontrib><creatorcontrib>Interrante, J. D.</creatorcontrib><creatorcontrib>Pathmanathan, I.</creatorcontrib><creatorcontrib>Patel, M. R.</creatorcontrib><creatorcontrib>Anyalechi, G.</creatorcontrib><creatorcontrib>Cavanaugh, J. S.</creatorcontrib><creatorcontrib>Kirking, H. L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Surie, D.</au><au>Interrante, J. D.</au><au>Pathmanathan, I.</au><au>Patel, M. R.</au><au>Anyalechi, G.</au><au>Cavanaugh, J. S.</au><au>Kirking, H. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>23</volume><issue>12</issue><spage>1308</spage><epage>1313</epage><pages>1308-1313</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>BACKGROUND: Tuberculosis preventive treatment (TPT) reduces the development of tuberculosis (TB) disease and mortality in people living with human immunodeficiency virus (HIV) infection. Despite this known effectiveness, global uptake of TPT has been slow. We aimed to assess
current status of TPT implementation in countries supported by the US President's Emergency Plan for AIDS Relief (PEPFAR).METHODS: We surveyed TB-HIV program staff at US Centers for Disease Control and Prevention (CDC) country offices in 42 PEPFAR-supported countries about current
TPT policies, practices, and barriers to implementation. Surveys completed from July to December 2017 were analyzed.RESULTS: Of 42 eligible PEPFAR-supported countries, staff from 35 (83%) CDC country offices completed the survey. TPT was included in national guidelines in 33 (94%)
countries, but only 21 (60%) reported nationwide programmatic TPT implementation. HIV programs led TPT implementation in 20/32 (63%) countries, but TB programs led drug procurement in 18/32 (56%) countries. Stock outs were frequent, as 21/28 (75%) countries reported at least one isoniazid
stock out in the previous year.CONCLUSION: Despite widespread inclusion of TPT in guidelines, programmatic TPT implementation lags. Successful scale-up of TPT requires uninterrupted drug supply chains facilitated by improved leadership and coordination between HIV and TB programs.</abstract><cop>France</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>31931915</pmid><doi>10.5588/ijtld.19.0018</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2019-12, Vol.23 (12), p.1308-1313 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2338091784 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome AIDS Communication Barriers Developing Countries Disease control Emergency preparedness Global Health Guidelines Health Policy Health Promotion HIV HIV Infections Human immunodeficiency virus Humans International Cooperation Isoniazid isoniazid preventive therapy Leadership Offices Policies Policy Polls & surveys Procurement Supply chains Surveys And Questionnaires Tuberculosis Tuberculosis, Pulmonary - prevention & control Viruses |
| title | Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A14%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_ingen&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Policies,%20practices%20and%20barriers%20to%20implementing%20tuberculosis%20preventive%20treatment-35%20countries,%202017&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Surie,%20D.&rft.date=2019-12-01&rft.volume=23&rft.issue=12&rft.spage=1308&rft.epage=1313&rft.pages=1308-1313&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.19.0018&rft_dat=%3Cproquest_ingen%3E2325598052%3C/proquest_ingen%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2325598052&rft_id=info:pmid/31931915&rft_ingid=iuatld/ijtld/2019/00000023/00000012/art00013&rfr_iscdi=true |